Net income
-164 million USD
2020-01-01 – 2020-12-31
Fundies. English
Urovant Sciences Ltd.
EDGAR12 filing records in this dataset, filed from 2018-07-13 to 2021-02-12. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 71.3 million USD Source
Exact value
71295000 USD
- Long-term debt including current maturities
- 209 million USD Source
Exact value
209285000 USD
- Shares outstanding
- 32.5 million shares Source
Exact value
32533959 shares
Reported share-count change
6.60% · 2.01 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Operating cash flow
-142 million USD
2020-01-01 – 2020-12-31
Exact inputs and evidence
- Operating cash flow: -102084000 USD · 2019-04-01 – 2020-03-31 Source
- Operating cash flow: -70531000 USD · 2019-04-01 – 2019-12-31 Source
- Operating cash flow: -30800000 USD · 2020-04-01 – 2020-06-30 Source
- Operating cash flow: -63440000 USD · 2020-04-01 – 2020-09-30 Source
- Operating cash flow: -30800000 USD · 2020-04-01 – 2020-06-30 Source
- Operating cash flow: -110269000 USD · 2020-04-01 – 2020-12-31 Source
- Operating cash flow: -63440000 USD · 2020-04-01 – 2020-09-30 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2021-02-12.
Financial data available through: 2020-03-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- operating income: No compatible figures in this window
- Net income: 3 of 11 periods available· newest 2020-03-31
- Operating cash flow: 3 of 11 periods available· newest 2020-03-31
- capital expenditure: No compatible figures in this window
- Total assets: 3 of 11 periods available· newest 2020-03-31
- Total liabilities: 3 of 11 periods available· newest 2020-03-31
- Current assets: 3 of 11 periods available· newest 2020-03-31
- Current liabilities: 3 of 11 periods available· newest 2020-03-31
- Cash and cash equivalents: 3 of 11 periods available· newest 2020-03-31
- long term debt: No compatible figures in this window
- Shares outstanding: 3 of 11 periods available· newest 2020-03-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 35.4 millionPrior period
−USD 111.35 million
–
Current period
−USD 146.75 million
–
Exact inputs and evidence
-146745000 − -111346000 = -35399000 USD
-111346000 USD · 2018-04-01 – 2019-03-31
Inspect prior input Prior source-146745000 USD · 2019-04-01 – 2020-03-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 6.95 millionPrior period
−USD 109.04 million
–
Current period
−USD 102.08 million
–
Exact inputs and evidence
-102084000 − -109036000 = 6952000 USD
-109036000 USD · 2018-04-01 – 2019-03-31
Inspect prior input Prior source-102084000 USD · 2019-04-01 – 2020-03-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2018 2017-04-01 – 2018-03-31 | −USD 37.07 million Exact valueExact value: -37074000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 34.09 million Exact valueExact value: -34086000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2018-04-01 – 2019-03-31 | −USD 111.35 million Exact valueExact value: -111346000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 109.04 million Exact valueExact value: -109036000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2020 2019-04-01 – 2020-03-31 | −USD 146.75 million Exact valueExact value: -146745000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 102.08 million Exact valueExact value: -102084000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
12 filings · 622 latest values · 622 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001740547, 1740547, UROV, edgar:1740547
Also known as Urovant Sciences Ltd.